Volume 5, 2nd Quarter 2018
The atmosphere is changing in global healthcare more than ever before. The landscape is hard to ignore and our environment is taking more health risks exposing Patients, Researchers and Providers with the evolving challenge to keep pace the International research community. The responding need and missed opportunity still vacant for many countries today. However we know predictively the participation has been increasing from those ancillary to Cannabis for quite some time, and today we find it hard to not see why when Patients are demonstrating in thirty states and nine countries independence from their own traditional ideologies as they take more management of their pain and conditions.
And then the day comes when the world was awakened to the recent news from the FDA with the anticipated announcement of the approval for the first CBD, Cannabis compound product Epidiolex. A historical first for the United States healthcare prescription market, and manufacturer GW Pharmaceuticals. GW is a UK based company releasing their oral treatment targeting seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome. The target demographic will range in ages from two years to the mature Patient. A moment in the making for GW and their Partners. As I have seen over the years the execution of relentless pursuit to traction effectively a market desperate to see the science support continued innovation and discovery for safe controlled outcomes.
I have long said “safe, effective medications traction scalability and sustainability”. From this moment forward we will see the evolution of this integrative approach from Academic Institutions, to teaching hospitals, and governments adopting and adapting to the rapid transformation towards the future of global healthcare fused with medical and clinical cannabis developments, and treatments.
Patients and Providers have equally sought solutions, and together history is fusing the opportunity for both to benefit. What a powerful moment in time to get it right.
Together we can bridge back the conversation between Patient and Providers, it begins with the science and continued pursuit of progressive research. This is the future of health sustainability.
In this issue we address challenges facing integrating markets merging in healthcare, advancing health and wellness offering innovative solutions that are support validation from Patients and Providers. The recent announcement from the FDA approving a CBD Cannabis oral treatment Epidiolex designed for Patients suffering indications associated with Dravet Syndrome,Lennox-Gastaut Syndrome and other epilepsies will forever transform the future of healthcare.
In health,
Amy
From the Editor in Chief:
4
5
Amy Berliner is the Founder/CEO or Aegis Biotech
& Editor-in-Chief of CannaHealthcare Magazine & President California Chapter Government Blockchain Association.